Transcranial Photobiomodulation for Reducing Autism Symptoms in Children - Open Label Study (TPBMASDOL) - Trial NCT06359080
Access comprehensive clinical trial information for NCT06359080 through Pure Global AI's free database. This phase not specified trial is sponsored by JelikaLite LLC and is currently Completed. The study focuses on Autism Spectrum Disorder. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
JelikaLite LLC
Timeline & Enrollment
N/A
May 08, 2022
Dec 11, 2022
Primary Outcome
Change in Autism Symptoms
Summary
The hypothesis of the study is that photobiomodulation reduces symptoms of autism.
 Participants will be children between the ages of 2 and 7, who have been diagnosed with
 moderate to severe autism. Transcranial photobiomodulation will be administered to the
 children in the experimental condition twice a week for 10 weeks. Results will be measured
 through parental interviews, standardized CARS2 (Childhood Autism Rating Scales, 2nd Edition)
 and data collected from EEG.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06359080
Device Trial